|
|
|
| Clinical Study on Taxol Combined with Carboplatin in Treating Epithelial Ovarian Cancer |
| LI Cheng-liang, XIN Hong, WANG Min-juan,et al |
| General Medicine Department, Xi'an Medical College First Affiliated Hospital, Shaanxi Xi'an 710077 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of taxol combined with carboplatin on epithelial ovarian cancer. 【Methods】 A total of 80 patients with epithelial ovarian cancer admitted in our hospital from August 2015 to July 2017 were divided into two groups on the basis of random number table, with 40 cases in each group. The observation group was treated with the combination of taxol and carboplatin, while the control group received carboplatin only. Both groups were treated continuously for 2 courses, each lasting 2 weeks. The clinical efficacy, adverse reactions, changes of tumor markers [carbohydrate antigen (CA) 199, CA125, CA153, carcino-embryonic antigen (CEA)], and immune function indicators [CD3+T ratio, CD4+ ratio, CD8+ T ratio and CD4+/CD8+ value] as well as Karnofsky performance status (KPS) scores were compared between the two groups before and after treatment between the two groups. 【Results】The effective rate of the observation group was 82.50% (33/40),which was much higher than that of the control group 57.50% (23/40) (P<0.05). The incidence of adverse reactions of the observation group was 27.50% (11/40) and that of the control group was 22.50% (9/40). The difference in the incidence of adverse reactions between the two groups was not statistically different (P>0.05). After treatment both groups obtained significantly lower content of serum CA199, CA125, CA153, CEA and lower peripheral blood CD3+, CD4+, CD4+/CD8+ values (P<0.05). On the other hand, the proportion of CD8+ in peripheral blood was significantly increased (P<0.05). The serum levels of CA199, CA125, CA153, CEA and CD8+ in the observation group were significantly lower than those in the control group (P<0.05), and the peripheral blood CD3+, CD4+ ratio and CD4+/CD8+ values were significantly increased (P<0.05). The KPS score of the observation group 3 months after treatment was obviously higher than that before treatment (P<0.05), but there was no significant change before and after chemotherapy in the control group (P>0.05). 【Conclusion】 The combination of taxol and carboplatin in treating epithelial ovarian cancer can significantly lower the expression levels of serum tumor markers, regulate cellular immune function and improve patients' life quality, which is worthy of clinical application.
|
|
Received: 11 July 2018
|
|
|
|
|
|
[1] 王颖欣,李昌英,何胜利.病理因素及化疗因素与上皮性卵巢癌预后关系分析[J].现代中西医结合杂志,2015,24(36):4066-4068.
[2] 边策,赵霞.新辅助化疗在晚期卵巢癌治疗中的应用[J].实用妇产科杂志,2015,31(4):263-266.
[3] 张国楠,朱熠,黄建鸣.紫杉醇在上皮性卵巢癌化疗中的双刃剑效应与对策思考[J].中国实用妇科与产科杂志,2017,33(1):21-24.
[4] 雷静,赵周社,史大鹏.实体瘤影像学疗效评价标准及其评估进展[J].功能与分子医学影像学(电子版),2015,4(1):58-64.
[5] 范淑英,王健,刘芸,等.紫杉醇联合卡铂周疗和三周疗法治疗卵巢癌的Meta分析[J].解放军医学杂志,2016,41(7):589-597.
[6] 宋丹,孔为民.紫杉醇联合卡铂治疗晚期及复发性宫颈癌的可行性研究[J].实用癌症杂志,2016,31(3):421-424.
[7] 王景胜,苗杰,刘正君,等.外周血T淋巴细胞亚群检测用于恶性肿瘤患者中的临床效果[J].检验医学与临床,2017,14(Z1):269-270.
[8] 张红旭,韩枫,黄金岳,等.恶性肿瘤患者T淋巴细胞亚群及NK细胞活性与抗菌药物使用相关性[J].中国药物警戒,2016,13(11):645-650.
[9] 熊雯,周新娥,黄娟,等.血清CA125、HE4及IL-17检测对上皮性卵巢癌的早期诊断价值分析[J].中国计划生育和妇产科,2016,8(3):69-73.
[10] Dede M, Gungor S, Yenen MC,et al.CA19-9 may have clinical significance in mature cystic teratomas of the ovary[J].Int J Gynecol Cancer,2006, 16 (1): 186-193. |
|
|
|
2018, Vol. 35 
